APOB and metabolic syndrome: In model 2, for patients with diabetes and atherogenic dyslipidemia, apoB levels were slightly over-estimated, as the estimated apoB was more than 150 mg/dl, whereas apoB levels were under-estimated in patients taking lipid-lowering agents.